|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First Author, Year | Country(TB Burdena) | % Male | Mean Age in Years (SD) | %HIV | % BCG | Other Study Population Comments | TST 5-mmSpecificity(95% CI, Interval) (N) | TST 10-mmSpecificity(95% CI, Interval) (N) | TST 15-mmSpecificity(95% CI, Interval) (N) | Quality Rating |
| Franken, 2007126 | Netherlands (L) | 91.8 | 19.6(2.8) | NR | 8.8 | Population is Dutch armed forces recruits. 2 subjects were known to have been treated previously for TB.  |  | 0.89(0.83 to 0.93)(153) | 0.92(0.87 to 0.95)(153) | Poor |
| Ozekinci, 2007103 | Turkey (I) | NR | 30Range: 17 to 61 | NR | 67.4b | Data extracted for subjects with no history of exposure to TB. |  | 0.46c(0.30 to 0.64)(28) |  | Poor |
| Shalabi, 2009108 | Egypt (I) | 58.1 | 39.4(12.6) | 0 | 77.4 | Data extracted for healthy control subjects.  |  | 0.84(0.67 to 0.93)(31) |  | Poor |

a TB burden according to World Health Organization classification. (L) Low <10 cases/100,000; (I) Intermediate 10–99 cases/100,000; (H) High >100 cases/100,000.

b Represents demographics of the overall study population; demographics for subjects eligible for inclusion in analysis were not reported.

c Estimate represents use of both the 10-mm and 15-mm threshold, which varied by BCG vaccination status of the individual tested.

**Abbreviations:** BCG=bacille Calmette-Guérin; CI=confidence interval; HIV=human immunodeficiency virus; M.Tb=*Mycobacterium tuberculosis*; NR=not reported; SD=standard deviation; TB=tuberculosis; TST=tuberculin skin test.